Gene therapy methods and compositions

Details Gene therapy methods and compositions Gene therapy methods and compositions

1995-06-07

1999-02-09

Ketter, James

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

435 691, 4353201, 435366, 536 235, A01N 6300

Patent

active

058690409

ABSTRACT:
The present invention relates to uses of mutant proto-oncogenes and oncoproteins expressed by the proto-oncogenes in inhibiting tumor growth and/or inhibiting the transformed phenotype. The preferred oncoprotein is a dominant, interfering mutant of a nuclear E2F transcription factor protein and is preferably a mutant E2F1 transcription factor protein. Methods of treating a target cell are described. Treatment is accomplished by administering to a target cell a dominant interfering mutant of a proto-oncogene in an effective amount. Treatment is also accomplished by administering to a target cell an oncoprotein in an effective amount. Compositions for such use are described as well.

REFERENCES:
patent: 4797368 (1989-01-01), Carter et al.
patent: 5139941 (1992-08-01), Muzyczka
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5595884 (1997-01-01), Androphy et al.
Barinaga, M. 1994 Science 266: 1326.
Marshall, E. 1995 Science 269: 1050-1055.
Crystal, R. 1995 Science 270: 404-410.
Orkin, S.H. et al. 1995 Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.
Herskowitz, I. 1987 Nature 329: 219-222.
Ransone, L. et al. 1990 Proc. Nat'l Acad. Sci USA 87: 3806-3810.
Johnson et al. 1994 Proc. Nat'l Acad. Sci USA 91: 12823-12827.
Helin et al. 1992 Cell 70: 337-350.
Flotte and Carter, "Adeno-associated virus vectors for gene therapy", (1995) Gene Therapy 2, 357-362.
Xiao, Li and Samulski, "Efficient Long-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-Associated Virus Vector", (1996) Journal of Virology, 70, 8089-8108.
Kaplitt, Leone, Samulski, Xiao, Pfaff, O'Malley and During, "Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain", (1994) Nature Genetics 8, 148-153.
Flotte et al., "Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector", (Proc. Natl. Acad. Sci. USA (1993) 90, 10613-10617.
Fisher et al. "Recombinant adeno-associated virus for muscle directed gene therapy", (Nature Medicine (1997) 3, 306-312.
Kessler et al., "Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein", (Proc. Natl. Acad. Sci. USA (1996)93, 14082-14087.
Okada et al., "Gene therapy against an experimental glioma using adeno-associated virus vectors", (1996) Gene Therapy 3, 957-964.
Clayman et al., "In Vivo Molecular Therapy with p53 Adenovirus for Microscopic Residual Head and Neck Squamous Carcinoma", (1995) Cancer Research 55, 1-6.
Hirschowitz et al., "In Vivo Adenovirus-Mediated Gene Transfer of the Escherichia coli Cytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-Fluorocytosine", (1995) Human Gene Therapy 6, 1055-1063.
Zhang et al., "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy", (1996) Proc. Natl. Acad. Sci. USA 93, 4513-4518.
Ko et al., "Molecular Therapy with Recombinant p53 Adenovirus in an Androgen-Independent, Metastatic Human Prostate Cancer Model", (1996) Human Gene Therapy 7, 1683-1691.
Bischoff et al., "An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells", (1996) Science 274, 373-376.
Ohwada et al., "Regional Delivery of an Adenovirus Vector Containing the Escherichia coli Cytosine Deaminase Gene to Provide Local Activation of 5-Fluorocytosine to Suppress the Growth of Colon Carcinoma Metastatic to Liver", (1996) Human Gene Therapy 7, 1567-1576.
Elshami et al., "Treatment of Pleural Mesothelioma in an Immunocompetent Rat Model Utilizing Adenoviral Transfer of the Herpes Simplex Virus Thymidine Kinase Gene", (1996) Human Gene Therapy 7, 141-148.
Eastham et al., "Prostate Cancer Gene Therapy: Herpes Simplex Virus Thymidine Kinase Gene Transduction Followed by Ganciclovir in Mouse and Human Prostate Cancer Models", (1996) Human Gene Therapy 7, 515-523.
Bramson et al., "Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12", (1996) Human Gene Therapy 7, 1995-2002.
Riley et al., "Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb.sup.+/- mice", (1996) Nature Medicine 2, 1316-1321.
Roth et al., "Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer", (1996) Nature Medicine 2, 985-991.
Xiaolan Qian, William C. Dougall, Maria E. Hellman & Mark I. Greene, "Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation", Oncogene 9(5) (1994), pp. 1507-1514.
Neyns, B. Teugels, E., Bourgain, C., Lissens, W., De Sutter, P., Burrer, M., De Greve, J., "Experimental Therapeutics", Proceedings of the American Association for Cancer Research, (Mar. 1995), vol. 36, p. 433.
Wilhelm Krek, David M. Livingston, Suman Shirodkar, "Binding to DNA and the Retinoblastoma Gene Product Promoted by Complex Formation of Different E2F Family Members", Science, (3 Dec. 1993), vol. 262, pp. 1557-1560.
Brown et al. Molecular and Cellular Biology, vol. 13 (11): 6849-6857, 1993.
Oliner et al. Nature, vol. 362, pp. 857-860, 1993.
Leng et al. Oncogene, vol. 10(7): 1275-82 Apr. 6, 1995.
Ali et al., The use of DNA viruses as vectors for gene therapy, Gene Therapy 1:367-384 (1994).
Helin et al., A cDNA encoding a pRB-binding protein with propertis of the transcription factor E2F, Cell , 70, 337-350 (1992).
Hijmans et al., E2F-5, a new E2F family member that interacts with p130 in vivo Mollecular and Celleular Biology, 15, 3082-3089 (1995).
Hoyle et al., Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F, Molecular and Cellular Biology, 13, 7802-7812 (1993).
Johnson et al., Oncogenic activity of the E2F1 gene, Proc. Natl. Acad. Sci. USA, 91, 12823-12827 (1994).
Kaelin et al., Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties, Cell, 70, 351-364 (1992).
Kovesdi et al., Identification of a cellular transcription factor involved in E1A trans-action, Cell, 45, 219-228 (1986).
Lees et al., The retinoblastoma protein binds to a family of E2F transcription factors, Molecular and Cellular Biology, 13, 7813-7825 (1993).
Mulligan, The basic science of gene therapy, Science, 260, 926-932 (1993).
Nabel et al., Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans, Proc. Natl. Acad. Sci. USA, 90, 11307-11311 (1993).
Sardet et al., E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle, Proc. Natl. Acad. Sci. USA, 92, 2403-2407 (1995).
Singh et al., Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation, The EMBO Journal, 13, 3329-3338 (1994).

Affiliated with

Also associated with

Rating

Gene therapy methods and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene therapy methods and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene therapy methods and compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1946628